ReviewGenes2019
Canine Melanomas as Models for Human Melanomas: Clinical, Histological, and Genetic Comparison.
Review in Genes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 2 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- The Comparative Oncology of Canine Malignant Melanoma in Targeted Therapy: A Systematic Review ofInternational journal of molecular sciences · 2024Pooled it
- Federated and Transfer Learning Methods for the Classification of Melanoma and Nonmelanoma Skin Cancers: A Prospective Study.Sensors (Basel, Switzerland) · 2023Pooled it
- Preclinical study of an optimized AAV cancer vaccine in a spontaneous canine model of oral melanoma.Molecular therapy. Oncology · 2026Article
- Phytochemical profile and proteomic landscape associated with antineoplastic activity ofVeterinary and animal science · 2026Article
- Article
- Epidemiology of Four Major Canine Tumours in the UK: Insights From a National Pathology Registry With Comparative Oncology Perspectives.Veterinary and comparative oncology · 2026Article
- Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor.Journal of veterinary internal medicine · 2026Article
- Survival of dogs with melanoma from a referral veterinary hospital in Japan.The Journal of veterinary medical science · 2026Article
- A Comparative Study of Melanocytic Tumours: Linking Portuguese Dogs and Cats to Human Cases.Veterinary and comparative oncology · 2026Article
- Modeling rare melanoma subtypes: mechanisms, microenvironments and translational opportunities.Frontiers in oncology · 2026Review
- Transcriptomic profiling of a canine malignant eyelid melanoma.Brazilian journal of veterinary medicine · 2026Article
- Case Report: Topical imiquimod (Aldara®) as a palliative option for extensive canine facial cutaneous melanocytoma.Frontiers in veterinary science · 2026Article
- Adenovirus mediated gene therapy in cell lines derived from canine oral melanoma.Frontiers in immunology · 2026Article
- Every Tumour Counts: A Comprehensive Overview of Canine Oncology in Portugal.Animals : an open access journal from MDPI · 2025Article
- Expression of Glutamatergic Signaling in Canine Oral Melanocytic Neoplasms.Veterinary sciences · 2025Article
- N-Cadherin-Mediated Epithelial-Mesenchymal Transition as a Prognostic Indicator in Canine Melanoma.Veterinary sciences · 2025Article
- Privacy preserving skin cancer diagnosis through federated deep learning and explainable AI.Scientific reports · 2025Article
- SOX Family Members Expression in Canine Oral Melanoma: Role of the SOX3 in Tumor Aggressiveness.Veterinary sciences · 2025Article
- Capacity for Compensatory Cyclin D2 Response Confers Trametinib Resistance in Canine Mucosal Melanoma.Cancers · 2025Article
- Pilot Study of Intratumoral Immunotherapy with Cowpea Mosaic Virus Nanoparticles: Safety in Refractory Canine Oral Tumors.Molecular pharmaceutics · 2025Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite recent genetic advances and numerous ongoing therapeutic trials, malignant melanoma remains fatal, and prognostic factors as well as more efficient treatments are needed. The development of such research strongly depends on the availability of appropriate models recapitulating all the features of human melanoma. The concept of comparative oncology, with the use of spontaneous canine models has recently acquired a unique value as a translational model. Canine malignant melanomas are naturally occurring cancers presenting striking homologies with human melanomas. As for many other cancers, dogs present surprising breed predispositions and higher frequency of certain subtypes per breed. Oral melanomas, which are much more frequent and highly severe in dogs and cutaneous melanomas with severe digital forms or uveal subtypes are subtypes presenting relevant homologies with their human counterparts, thus constituting close models for these human melanoma subtypes. This review addresses how canine and human melanoma subtypes compare based on their epidemiological, clinical, histological, and genetic characteristics, and how comparative oncology approaches can provide insights into rare and poorly characterized melanoma subtypes in humans that are frequent and breed-specific in dogs. We propose canine malignant melanomas as models for rare non-UV-induced human melanomas, especially mucosal melanomas. Naturally affected dogs offer the opportunity to decipher the genetics at both germline and somatic levels and to explore therapeutic options, with the dog entering preclinical trials as human patients, benefiting both dogs and humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.